FY2025 EPS Estimates for Denali Therapeutics Inc. Cut by Analyst (NASDAQ:DNLI)

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research note issued to investors on Tuesday, September 3rd. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of ($2.65) for the year, down from their previous estimate of ($2.60). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.54) per share. Leerink Partnrs also issued estimates for Denali Therapeutics' FY2026 earnings at ($2.90) EPS, FY2027 earnings at $0.30 EPS and FY2028 earnings at $0.40 EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.09. The firm had revenue of $1.00 million for the quarter, compared to analyst estimates of $10.00 million. The firm's revenue for the quarter was down 99.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.30 earnings per share.

A number of other equities analysts have also recently issued reports on the company. Citigroup lifted their target price on Denali Therapeutics from $26.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Wedbush decreased their target price on Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, August 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 target price on shares of Denali Therapeutics in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on Denali Therapeutics from $28.00 to $29.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 10th. Finally, Bank of America raised their target price on Denali Therapeutics from $25.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $38.30.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI remained flat at $25.25 during mid-day trading on Friday. The company had a trading volume of 695,238 shares, compared to its average volume of 1,129,859. The stock has a market capitalization of $3.60 billion, a PE ratio of -26.30 and a beta of 1.40. The business has a fifty day moving average price of $23.26 and a 200-day moving average price of $20.77. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $25.90.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the firm's stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $22.12, for a total transaction of $663,600.00. Following the transaction, the director now directly owns 34,404 shares in the company, valued at $761,016.48. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 7.90% of the company's stock.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently bought and sold shares of the stock. CWM LLC raised its holdings in Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company's stock valued at $43,000 after buying an additional 1,376 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock worth $48,000 after purchasing an additional 1,847 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Denali Therapeutics by 48.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company's stock worth $53,000 after purchasing an additional 807 shares during the period. Fisher Asset Management LLC bought a new position in shares of Denali Therapeutics in the fourth quarter worth about $59,000. Finally, Assetmark Inc. increased its stake in shares of Denali Therapeutics by 65.3% in the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company's stock worth $76,000 after purchasing an additional 1,402 shares during the period. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.